BEST COMPANY IN AN EMERGING MARKET Validation project • Beximco Pharmaceuticals • Neurocrine BioSciences’s RE-KINECT prospective • Biocon real-world dyskinesia screening study and registry in • CinnaGen Pharmaceutical Group patients taking antipsychotics Scrip Awards • Hutchison China MediTech (Chi-Med) • Mundipharma BEST PARTNERSHIP ALLIANCE • WuXi Biologics • Bicycle Therapeutics and Bioverativ for hemophilia and sickle cell disease using bi-cyclic peptides BEST CONTRACT RESEARCH ORGANIZATION – • Evotec and Sanofi’s strategic collaboration to FULL-SERVICE PROVIDERS establish a new open innovation platform Finalists • CMIC Group • F-star and Denali Therapeutics to develop a multi- antibodies in immuno-oncology • Covance specific platform for delivery of medicines across the • Halozyme and Bristol-Myers Squibb • ICON blood-brain barrier for the use of ENHANZE drug delivery • IQVIA • Neurocrine and AbbVie for elagolix in technology in immuno-oncology drugs www.scripawards.com • PAREXEL women’s health 2018 • Worldwide Clinical Trials • and the University of Pennsylvania for EXECUTIVE OF THE YEAR, FOR LARGE & MEDIUM CAR-T medications in pediatric cancer patients CAP COMPANIES – SPONSORED BY LACHMAN BEST CONTRACT RESEARCH ORGANIZATION – • Roche and Ionis Pharmaceuticals to develop CONSULTANTS SPECIALIST PROVIDERS antisense drugs for Huntington’s disease • Alan Hirzel, CEO of Abcam • Cytel • John Maraganore, CEO of Alnylam • Illingworth Research Group FINANCING DEAL OF THE YEAR – PUBLIC • Edwin Moses, CEO of Ablynx • PHASTAR • Ablynx’s $200m US IPO on • Vas Narasimhan, CEO of Novartis • Quanticate • Horizon Discovery Group’s £80m public placing • Niels Riedemann, CEO co-founder of InflaRx We are delighted to announce the • Simbec-Orion • InflaRx’s $100m IPO and secondary offering • Jan van de Winkel, CEO of Genmab • Tioga Research • Morphosys’ $239m overallotment issue and shortlist for the 14th Annual Scrip Awards. NASDAQ listing EXECUTIVE OF THE YEAR, FOR SMALL CAP & PRIVATE BEST TECHNOLOGICAL DEVELOPMENT IN CLINICAL • Polyphor’s CHF165m IPO PHARMA COMPANIES – SPONSORED BY LACHMAN Over the summer, our panel of 17 respected judges has reviewed TRIALS - CLINICAL SPONSOR-FOCUSED • resTORbio’s $163m Series A to IPO CONSULTANTS all the entries to produce a shortlist that displays the wealth of • Covance’s Xcellerate CRA Dashboard • Eduardo Bravo, CEO of TiGenix • Cytel’s OK GO software FINANCING DEAL OF THE YEAR – PRIVATE • Jurgi Camblong, CEO and founder of innovation, dedication and hard work that the pharmaceutical and • ICON’s FIRECREST Pre-Screen • AstraZeneca/MedImmune’s $250m financing for SOPHiA GENETICS biotech industries have shown over the past year. • IQVIA’s Mobile SVR application spin-out Viela Bio • Carl Firth, CEO and founder of • Novartis’s Nerve Live • BioNTech’s $270m Series A financing ASLAN Pharmaceuticals • PAREXEL’s Perceptive Cloud • Crescendo Biologics’ $70m Series B financing • Antony Loebel, executive vice president, chief The full range of industry activities from big pharma, biotech • Enterprise Therapeutics’ £29m ($41m) medical officer, head of global clinical development companies and CROs is represented: from novel deals, to new BEST TECHNOLOGICAL DEVELOPMENT IN CLINICAL Series B financing of Sunovion Pharmaceuticals drug launches and finding technological breakthroughs in clinical TRIALS – TECH SPONSOR-FOCUSED • NodThera’s £28m Series A financing • Amy Schulman, CEO and co-founder of Lyndra • Bioclinica’s Bioclinica Clinical Adjudication • PhoreMost’s £11m ($15m) Series A financing • Raman Singh, CEO of Mundipharma Singapore trials. The Scrip Awards provides the industry with an opportunity • CluePoints’ Intelligent Central Statistical to acknowledge its highest achievers across all parts of the Monitoring Solution IQVIA’S CLINICAL ADVANCE OF THE YEAR AWARD WUXI APPTEC’S BIOTECH value chain, and to recognize both corporate and individual • Ergomed/PrimeVigilance/Automation Anywhere’s • Ablynx’s Phase III HERCULES study of caplacizumab COMPANY OF THE YEAR AWARD robotic process automation software for acquired thrombotic thrombocytopenic purpura • AveXis achievement. • ERT’s Advanced Imaging Technology Solution • Alexion Pharmaceuticals’ Phase III REGAIN study of • Bicycle Therapeutics • Medidata’s Medidata Rave Engage Soliris (eculizumab) in myasthenia gravis • Diurnal Group As in previous years, we will be announcing the winner of the • Phesi’s real-time data collection and analysis • bluebird bio’s Northstar-2 study of LentiGlobin in • F-star beta-thalassemia • Genmab Pharma Company of the Year Award (sponsored by CMIC) on COMMUNITY PARTNERSHIP OF THE YEAR AWARD – • GW Pharmaceuticals’ Phase III GWPCARE4 trial of • Neurocrine Biosciences the night, just as we do for the Lifetime Achievement Award SPONSORED BY MEDIDATA SOLUTIONS Epidiolex for refractory epilepsy (sponsored by ICON). We are thrilled that so many of you have • AstraZeneca’s Mentoring Team • Ipca Laboratories Phase IV study of BUSINESS DEVELOPMENT TEAM OF THE YEAR – • Beximco Pharma with DSM Nutritional Products and hydroxychloroquine in type 2 diabetes mellitus SPONSORED BY SKIPTA taken the time to enter, and sorry that not everyone can make Sight & Life Global Nutrition Research Institute to in India • AstraZeneca and Avillion partnership team the shortlist. improve nutrition in rural Bangladesh • Nanobiotix’s Phase I/II trial of nanomedicine • Bicycle Therapeutics’ business development team • IQVIA India’s Race for 7 with the Organization for NBTXR3 in head and neck cancer • CinnaGen’s business development team Rare Diseases India • Evotec’s business development team This year’s winners will be announced at a glittering black tie • Oxford PharmaGenesis’ Open Pharma LICENSING DEAL OF THE YEAR – • F-star’s business development team ceremony at the Hilton on Park Lane on November 28. SPONSORED BY WORLDWIDE CLINICAL TRIALS • Rentschler Biopharma/Leukocare alliance business BEST USE OF REAL-WORLD EVIDENCE • AiCuris and Merck & Co (MSD) for Prevymis development team • Biogen/ICON’s New insights into the burden and (letermovir) for cytomegalovirus Congratulations to all our finalists and good luck on the night! costs of multiple sclerosis in Europe • AstraZeneca and Merck & Co (MSD) for Lynparza SYNEOS HEALTH’S BEST NEW DRUG AWARD • ICON’s Transthyretin Amyloidosis Outcomes and selumetinib • Kite Pharma/Gilead Sciences’ Yescarta Survey (THAOS) • AstraZeneca and Pearl Therapeutics for PT027 (axicabtagene ciloleucel) • ICON/Vertex’s study of lumacaftor/ivacaftor lung in asthma • Novartis’s Kymriah (tisagenlecleucel) For information on table bookings and sponsorship contact: function decline in patients with cystic fibrosis • Emergent BioSolutions and Valneva for the Zika • Roche’s Hemlibra (emicizumab) • IQVIA/Bristol-Myers Squibb’s I-O Optimise vaccine candidate VLA1601 • Spark Therapeutics’ Luxturna (voretigene Christopher Keeling | [email protected] collaboration in patients with a thoracic malignancy • F-star (through F-star Delta) and Merck KGaA neparvovec-rzyl) T +44 (0) 203 377 3183 | M +44 (0) 7917 647 859 • Multiple Sclerosis Algorithms Development and for five bispecific • TiGenix’s Alofisel (darvadstrocel)

Headline Sponsor Sponsored by

JN0000 Scrip Awards 2018 Finalist DPS_3.indd 1 2018/09/25 10:35